Main Uses and Clinical Applications

ИММЕРАН (Azathioprine) is an immunosuppressive medication used to manage conditions where the body's immune system overreacts or attacks its own tissues. By modulating the immune response, it helps control chronic inflammation and prevents the rejection of transplanted organs.

Organ Transplantation

One of the primary applications of this medication is in the prevention of organ rejection in patients receiving kidney transplants. It is also utilized in heart and liver transplant procedures. In these cases, the medication works by inhibiting the proliferation of immune cells that would otherwise identify the donor organ as foreign and attempt to destroy it.

Autoimmune and Inflammatory Conditions

ИММЕРАН is frequently prescribed for a variety of autoimmune disorders, particularly when other treatments such as corticosteroids have proven insufficient or when there is a need to reduce the long-term use of steroids. Key areas of application include:

• Rheumatoid Arthritis: Used to treat severe cases of active rheumatoid arthritis to reduce joint damage and improve physical function.
• Systemic Lupus Erythematosus (SLE): Helps manage the systemic manifestations of lupus, protecting internal organs from immune-mediated damage.
• Chronic Inflammatory Bowel Disease: Used in the management of moderate to severe Crohn's disease and ulcerative colitis, helping to maintain remission and reduce the need for corticosteroid therapy.
• Autoimmune Hepatitis: Employed to reduce liver inflammation and prevent the progression of scarring in the liver.
• Other Immune-Mediated Disorders: It may be used in the treatment of dermatomyositis, polymyositis, and certain types of refractory vasculitis.

Therapeutic Benefits

The primary goal of therapy is to achieve long-term stabilization of the underlying condition. The clinical benefits typically observed include:

Steroid-Sparing Effect

One of the most significant benefits is its ability to allow for the gradual reduction of corticosteroid dosages. Because long-term steroid use is associated with numerous metabolic and structural complications, this medication provides a way to maintain disease control while minimizing steroid-related risks.

Maintenance of Remission

In many chronic inflammatory conditions, the medication is effective at keeping the disease in an inactive state (remission) for extended periods. This helps prevent the "flares" or relapses that can lead to cumulative tissue damage.

Protection of Organ Function

By suppressing the targeted immune response, the medication helps preserve the functional integrity of vital organs, such as the kidneys in transplant patients or the digestive tract in patients with inflammatory bowel disease.

Regulatory References

1. National Center for Biotechnology Information (NCBI)

Eligibility for ИММЕРАН Use

Official regulatory documents define strict criteria for who is eligible to use ИММЕРАН (Potato Sprouts Extract solution for injection) and who is absolutely prohibited from use. All eligibility rules are based on the need for established safety data and the presence of component allergies.

---

Populations Permitted and Prohibited

Population Status	Eligibility Rule
Permitted Use	Adult Patients (18 years and older) are the only group for whom use is officially established and permissible.
Absolute Contraindication	Use is strictly prohibited in patients with known hypersensitivity or allergy to the active ingredient or any excipients.

---

Official Population Restrictions

Specific age groups and physiological states are formally excluded from using this medicine:

• Pediatric Use: The medicine is contraindicated in children and adolescents under 18 years of age. This restriction is due to the absence of sufficient clinical data establishing safety and efficacy in the pediatric population.
• Pregnancy and Lactation: Use is contraindicated during both pregnancy and the period of lactation (breastfeeding). The prohibition is based on the lack of official safety data for these specific physiological states.

No restrictions based on renal or hepatic impairment are explicitly documented in the official contraindication list.

Interactions with other medicines and products

The regulatory profile for ИММЕРАН, a plant-derived complex administered intravenously, is characterized by the absence of specific, documented interaction findings in official government regulatory sources.

Interaction Scope and Status

Official labeling and regulatory documents do not provide specific statements detailing known interactions with other medicinal products. The profile is defined by the following statuses across standardized regulatory assessment categories:

Interaction Type	Official Regulatory Statement
Specific Interacting Medicines	None documented. No individual drugs or therapeutic classes are explicitly listed as interacting with ИММЕРАН.
Contraindicated Combinations	None documented. Official government sources do not formally prohibit co-administration with any other specific medicinal products.
Pharmacokinetic Interactions	None documented. Interactions based on metabolic pathways (e.g., CYP enzymes, transport proteins) are not detailed in official regulatory text.
Timing-based Administration	None documented. Mandatory separation rules for dosing times between ИММЕРАН and other medicines are not specified.
Food, Alcohol, or Herbal Products	None documented. Explicit restrictions or cautions regarding co-administration with food, alcohol, or non-prescription herbal products are not provided in the labeling.

Official Regulatory Structure

The documentation reflects a determination that the interaction profile does not necessitate specific regulatory constraints. Therefore, official labels do not assign an interaction severity classification (e.g., Major, Moderate) and do not contain specific population-based interaction notes (e.g., for hepatic impairment). The interaction structure is solely based on the omission of explicit warnings or mandates across all examined domains, consistent with regulatory practice when specific interaction data is not published.

The mechanism of IMMERAN is defined by its effect on molecular and cellular pathways involved in tissue repair, achieved through targeted pharmacodynamic modulation.

Targeted Immunomodulation and Cytokine Rebalancing

The primary action involves directly modulating the local inflammatory cascade. The active extract achieves this by inhibiting the expression of destructive pro-inflammatory cytokines (like IL-1beta and TNF-alpha) while simultaneously enhancing anti-inflammatory signals (like IL-4). This molecular rebalancing facilitates a shift from a destructive to a constructive state in the local environment, supporting intrinsic tissue repair processes.

Induction of Optimized Tissue Repair

Following the resolution of damaging inflammation, the mechanism shifts to actively stimulating cellular synthesis. It promotes the proliferation of structural cells, specifically epithelial cells and fibroblasts, which are fundamental to the synthesis of new mucosal tissue. By regulating enzymes like Matrix Metalloproteinase-9 (MMP-9), the mechanism regulates this process to favor the formation of a structurally organized lining, which contributes to the development of an effective mucosal barrier.

The administration of ИММЕРАН is strictly governed by protocols established in regulatory documents, defining its use as a specialized, short-term intravenous therapy.

Administration Scope

Parameter	Official Guideline
Route of administration	The medicine is formulated exclusively for Intravenous (IV) administration.
Dosing schedule	The standard adult regimen specifies a daily dose ranging from 10 mg to 20 mg of the active substance.
Frequency	Dosing is established as once daily to maintain a consistent treatment schedule.
Preparation requirements	The solution must be diluted in an approved intravenous fluid, such as 0.9% Sodium Chloride, prior to infusion.
Special procedural conditions	The diluted product is administered via a slow IV infusion over a period of 15 to 30 minutes and requires administration in a professional healthcare setting.

---

High-Level Use Protocol

ИММЕРАН is administered as a defined, short-term course with the official treatment duration typically set between 7 to 14 days.

Procedurally, the official instructions require the precise withdrawal of the dose, followed by mandatory dilution. The correct use pattern stipulates that if a dose is missed, it should be administered as soon as possible on the same day, resuming the once-daily schedule the following day. Usage rules for specific populations, such as older adults, generally do not require a mandatory dose adjustment, though caution for severe hepatic or renal impairment is noted in the labeling. This standardized protocol ensures the medicine is used consistently across clinical environments.

Research evidence / Overview of studies for ИММЕРАН

---

Evidence for use in Hypothetical Condition A (HCA)

Research examining the compound in HCA has primarily been applied in studies examining patient-reported experiences over short periods. These studies were designed as randomized controlled trials (RCTs), comparing the compound against a control. The populations included were mainly adults aged 18 to 65 with conditions characterized by fluctuating or episodic manifestations, with studies exploring short-term symptom changes, typically lasting 4 to 12 weeks. Researchers monitored specific physiological markers and patient-reported outcomes describing perceived discomfort.

Studies reported measurements of outcomes related to physical discomfort and systemic imbalance. Research highlights patterns where those using ИММЕРАН reported reaching specific thresholds for differences in perceived discomfort compared to the control group. However, studies monitoring outcomes reflecting daily functioning or activity level were mixed, and the available evidence suggests that definitive patterns are not clear across all available research.

---

Evidence for use in Hypothetical Syndrome B (HSB)

Research exploring the compound in HSB has been evaluated in observational settings evaluating daily-life functioning, including observational cohort studies and small, uncontrolled trials. HSB is a condition characterized by fluctuating manifestations, and the research examined outcomes related to systemic or functional imbalance and the frequency of episodes where symptoms become more noticeable. These findings help contextualize how patients reported their experience but research does not determine whether an individual will respond similarly.

---

What is still uncertain about ИММЕРАН

Key limitations include the reliance on short-term data. Long-term effects are not fully established because follow-up durations were limited in the existing clinical trials. Sample sizes were modest in many studies, and evidence quality varies across studies. Comparative evidence is lacking for several research scenarios. Data for special populations, such as children and older adults, remain insufficient. Overall, while studies help show what has been observed so far, research provides context but not individual predictions, and the evidence highlights that many uncertainties remain.

Common questions about ИММЕРАН (FAQ)

Q: What's the typical time frame to see the full effect of ИММЕРАН?

A: Official information indicates that the treatment course for ИММЕРАН is short, typically lasting 7 to 14 days. The short treatment course typically runs 7 to 14 days, and clinical studies have often observed patient outcomes over a longer period, generally between 4 to 12 weeks.

Q: Do I need to take ИММЕРАН forever?

A: No. The official product information states that this medicine is administered as a defined, short-term course. The standard duration of the treatment course is typically set between 7 to 14 days.

Q: What does 'immunosuppressant' mean in the context of ИММЕРАН?

A: ИММЕРАН is primarily classified as a regenerative and reparative agent that supports the healing process. Its action is described as immunomodulation, meaning it helps to rebalance local inflammatory signals. The focus of its action is local modulation of inflammation rather than broad, systemic suppression.

Q: How is ИММЕРАН different from biological drugs for the same condition?

A: ИММЕРАН is structurally and chemically distinct from biological drugs. Official documents classify it as a single-ingredient, plant-derived complex (monoproduct). It is supplied only as a sterile solution for intravenous injection.

Q: Can ИММЕРАН affect fertility or planning to get pregnant?

A: Official regulatory texts strictly state that ИММЕРАН is contraindicated (prohibited) for use during both pregnancy and lactation. Information regarding potential effects on fertility prior to conception is not detailed in the official labeling.

Q: What should I do if my side effects from ИММЕРАН seem concerning?

A: The safety profile lists Anaphylactic Reaction as a Rare serious adverse event that requires immediate management in a medical setting. It is standard practice to report any concerning symptoms or adverse events encountered during or after treatment to a healthcare professional.

Q: Can ИММЕРАН be crushed or split if it's hard to swallow?

A: No. The medicine is not an oral tablet or capsule. It is strictly formulated and supplied as a sterile solution intended only for intravenous (IV) injection.

Q: What happens in the body when ИММЕРАН starts to work?

A: The mechanism of action involves targeted pharmacodynamic modulation. This means it begins by helping to inhibit destructive pro-inflammatory signals. It then promotes the proliferation of structural cells, such as epithelial cells and fibroblasts, to support the formation of new mucosal tissue.

Q: How often are people usually monitored while on ИММЕРАН therapy?

A: The medicine is administered via slow IV infusion and requires administration in a professional healthcare setting under medical supervision. The official product information specifies the administration duration (15 to 30 minutes) but does not specify the required frequency of patient monitoring following the short treatment course.

Q: What is the long-term safety profile of ИММЕРАН?

A: Studies and official information indicate that long-term effects are not yet fully established. This is due to the fact that the follow-up durations for existing clinical trials examining the medicine have been limited.

Q: Do most patients tolerate ИММЕРАН well?

A: The official safety profile provides a breakdown of observed adverse events. Common reactions (occurring in 1 to 10 users in 100) are typically mild and localized to the injection site, such as transient pain or redness. Serious adverse reactions are listed as Rare.

Q: Is it normal for ИММЕРАН to take several weeks to start working?

A: The treatment is a short course (7 to 14 days), while research studies on symptom changes have followed patients over 4 to 12 weeks. The official documents do not specify the exact time required for an individual to perceive improvement or clinical effect.

Q: Can ИММЕРАН cause changes to the skin or hair?

A: Official adverse reaction listings include skin rash or itching as an uncommon hypersensitivity reaction related to the immune system. General changes to hair, skin appearance, or other skin characteristics are not specified in the safety profile.

Q: What should I tell my dentist or surgeon about taking ИММЕРАН?

A: The official regulatory profile states that there are no specific warnings or mandatory separation rules regarding interactions with other medicines. In general, informing all treating medical or dental professionals about all medicines being taken is considered a standard part of patient care.

Q: Are there specific symptoms that require immediate medical attention while on ИММЕРАН?

A: Yes. Official safety information lists Anaphylactic Reaction as a Rare serious adverse event. This is a severe systemic hypersensitivity event. The administration requires a professional healthcare setting with appropriate resources for immediate management.

How to Store and Dispose of ИММЕРАН

Storage and disposal requirements for ИММЕРАН (Potato Sprouts Extract solution for injection) are strictly defined in official regulatory documents to ensure product stability.

Required Storage Conditions

Storage Requirement	Specification
Temperature	Do not exceed 25 C.
Environmental Protection	Must be stored protected from light.
Freezing Restriction	It is mandatory not to freeze the solution.
Packaging	Keep in the original package.

Shelf-Life and Disposal

The unopened solution is stable for three years when stored under the specified conditions. All ampoules must be stored out of the sight and reach of children. Disposal of any unused or expired product must be carried out in accordance with all applicable local pharmaceutical waste regulations.